Search

everythinglearnresearchcommunity

for

Search:↓

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Combining glucocorticoids with immunosuppressants like cyclophosphamide improves remission and reduces relapse in pemphigus patients.

HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

B cells can both help and hinder the body's defense against melanoma.

Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.

Repeated biopsies are crucial for managing lupus panniculitis when initial treatments fail.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Tadalafil and Finasteride may help treat aggressive melanoma.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Ruxolitinib can cause a delayed skin reaction on the nose.

Adalimumab can cause hair loss and scalp issues in some psoriasis patients.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

JAK inhibitors are effective treatments for alopecia areata.

Rituximab may cause skin issues, but baricitinib can help improve them.

Dupilumab can cause unexpected scalp issues, so early symptom recognition is important to avoid hair loss.

Dupilumab for atopic dermatitis can cause mild skin issues in some patients.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Apremilast did not work for treating severe alopecia areata.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Mycophenolate mofetil helped reduce steroid use in treating a dog's autoimmune skin disease.

Rituximab can cause skin issues, but baricitinib may help improve them.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.